Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artivion, Inc. Common Stock (NY:AORT)

19.95 -0.69 (-3.34%)
Delayed Quote Updated: 12:07 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Artivion, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Artivion Q3 Earnings Call Highlights ↗
Artivion (NYSE:AORT) reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for... 
Via MarketBeat
Topics Earnings
News headline image
Artivion (AORT) Q3 2026 Earnings Call Transcript ↗
Margins slipped on ramp costs as the company eyes NEXUS and ARTIZEN milestones. 
Via The Motley Fool
Topics Earnings
News headline image
AORT Q3 2026 deep dive: stent graft growth and NEXUS launch preparations shape outlook
Medical device company Artivion (NYSE:AORT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 9.2% year on year to $123.8 million. On the oth... 
Via StockStory
ARTIVION INC (NYSE:AORT) Q3 EPS Beat Meets Inline Revenue ↗
Via Chartmill
News headline image
3 of Wall Street’s favorite stocks we find risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Artivion’s (NYSE:AORT) Q3 2026 sales beat estimates
Medical device company Artivion (NYSE:AORT) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 9.2% year on year to $123.8... 
Via StockStory
Topics Earnings
News headline image
Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona shares are soaring, what you need to know
What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat... 
Via StockStory
News headline image
Artivion (AORT) to report earnings tomorrow: here is what to expect
Medical device company Artivion (NYSE:AORT) will be announcing earnings results this Thursday after the bell. Here’s what to expect. Artivion beat analysts’ ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its ... 
Via StockStory
News headline image
1 Small-Cap Stock with Exciting Potential and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
Topics Economy
News headline image
2 Growth Stocks with All-Star Potential and 1 We Find Risky
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 Profitable Stocks We Approach with Caution
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wo... 
Via StockStory
Topics Supply Chain
News headline image
3 Russell 2000 Stocks Walking a Fine Line
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
Topics Energy
News headline image
1 High-Flying Stock to Own for Decades and 2 Facing Challenges
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
Why Artivion (AORT) Stock Is Trading Up Today
What Happened? Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on ... 
Via StockStory
Topics Earnings
News headline image
Artivion (AORT) Q2 2026 Earnings Call Transcript ↗
Revenue grew 9% as heart valve and stent graft products drove results. 
Via The Motley Fool
Topics Earnings
News headline image
5 Revealing Analyst Questions From Artivion’s Q2 Earnings Call
Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve po... 
Via StockStory
Topics Earnings
News headline image
Artivion Q2 Earnings Call Highlights ↗
Artivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in... 
Via MarketBeat
Topics Earnings
News headline image
AORT Q2 Deep Dive: Product Momentum and Pipeline Expansion Support Positive Outlook
Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 ... 
Via StockStory
News headline image
Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers
Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 mil... 
Via StockStory
News headline image
Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after the bell. Here’s what to expect. Artivion met analysts’ revenue ex... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
3 Small-Cap Stocks We Keep Off Our Radar
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
3 Reasons to Sell AORT and 1 Stock to Buy Instead
Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its ... 
Via StockStory
Topics Supply Chain
News headline image
3 Stocks Under $50 with Warning Signs
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
2 Growth Stocks Set to Flourishand 1 We Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Topics Electric Vehicles World Trade
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.